Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2023

Open Access 01-12-2023 | Lymphoma | Correspondence

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Authors: Qiusha Huang, Xiao-hui Zhang, Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.
Literature
1.
Hou J-Z, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021;14(1):66.CrossRefPubMedPubMedCentral
2.
Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517–28.CrossRefPubMedPubMedCentral
3.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human. Phase I Trial J Clin Oncol. 2021;39(30):3340–51.PubMed
4.
Chiesa R, Georgiadis C, Ottaviano G, Syed F, Braybrook T, Etuk A, Zhan H, Gkazi SA, Preece R, Adams S, Thomas R, Awuah A, Gilmour K, Mhaldien L, Chu J, Pinner D, Kubat A, Veys P, Rao K, Lucchini G, O’Connor D, Vora A, Qasim W. Tvt CAR7: phase 1 clinical trial of base-edited "universal” CAR7 T cells for paediatric relapsed/refractory T-ALL. Blood. 2022;140(Supplement 1):4579–80.CrossRef
5.
Zhang X, Zhou Y, Yang J, Li J, Qiu L, Ge W, Pei B, Chen J, Han L, Ren J, Lu P. A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood. 2022;140(Supplement 1):4566–7.CrossRef
6.
Tan Y, Pan J, Deng B, Ling Z, Weiliang S, Tian Z, Cao M, Xu J, Duan J, Wang Z, Wang K, Li C. Efficacy and safety of donor-derived CD7 CAR T cells for r/r T-cell acute lymphoblastic leukemia/lymphoma: interim analysis from a phase 2 trial. Blood. 2022;140(Supplement 1):4602–3.CrossRef
7.
Wong XFA, Ng J, Zheng S, Ismail R, Qian H, Campana D, Tan YX. Development of an off-the-shelf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing. Blood. 2022;140(Supplement 1):2358–9.CrossRef
8.
Qian H, Gay FPH, Pang JWL, Lee Y, Ang J, Tan HC, Lek ES, Campana D, Tan YX. Development of anti-CD3 chimeric antigen receptor (CAR)-T cells for allogeneic cell therapy of peripheral T-cell lymphoma (PTCL). Blood. 2022;140(Supplement 1):4510–1.CrossRef
Metadata
Title
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
Authors
Qiusha Huang
Xiao-hui Zhang
Delong Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-023-01406-8

Other articles of this Issue 1/2023

Journal of Hematology & Oncology 1/2023 Go to the issue

Review

Ten years of ruxolitinib for myelofibrosis: a review of safety

Review

Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities

Correspondence

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia

Review

Metabolism, metabolites, and macrophages in cancer

Correspondence

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Research

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits